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ABSTRACT
Objectives To estimate the risk of developing cancer
in relation to the typical radiation doses received from a
range of X-ray guided cardiac catheterisations in
children, taking variable survival into account.
Methods Radiation doses were estimated for 2749
procedures undertaken at five UK hospitals using Monte
Carlo simulations. The lifetime attributable risk (LAR) of
cancer incidence was estimated using models developed
by the Biological Effects of Ionising Radiation committee,
based on both normal life expectancy, and as a function
of attained age, from 20 to 80 years, to take reduced
life expectancy into account.
Results The radiation-related risks from these
procedures are dominated by lung and breast cancer (for
females). Assuming normal life expectancy, central LAR
estimates for cancer incidence, based on median doses,
ranged from <1 in 2000 for atrial septal defect
occlusions to as high as 1 in 150 for valve replacements.
For a reduced life expectancy of 50 years, estimated risks
are lower by a factor of around 7. For conditions with
especially poor survival (age 20 years), such as
hypoplastic left heart syndrome, estimated cancer risks
attributable to radiation were <1 in 20 000.
Conclusions Based on recent UK radiation dose levels,
the risk of cancer following cardiac catheterisations is
relatively low and strongly modified by survival and the
type of procedure. The risk of breast cancer, especially
following pulmonary artery angioplasty and valve
replacements, is the greatest concern.
INTRODUCTION
Cardiac catheterisations have an established role in
the management of acquired and congenital heart
conditions. The procedure involves guidance using
X-rays, exposure to which is associated with an
increased lifetime risk of developing cancer.1 We
have previously reported on the radiation doses
from these procedures,2 concluding that doses have
fallen significantly over than last two decades in the
UK, despite the introduction of increasingly
advanced interventions, including transcatheter
valve replacements.3
A knowledge of the potential long-term risks fol-
lowing X-ray exposures is essential in the practices
of justification and optimisation, as well as commu-
nication with patients and parents and obtaining
informed consent. Direct epidemiological evalu-
ation of risks from low dose exposures is problem-
atic, due to the requirement of large sample sizes
and controlling for confounding factors.4 Potential
risks can also be estimated using models derived
from other exposed populations, most notably sur-
vivors of the atomic bombings of Hiroshima and
Nagasaki. This approach is not limited by sample
size, though still involves uncertainties relating to
the magnitude of risk per unit dose, the modifying
effect of age at exposure, and transfer of risks to
non-Japanese populations.
In this study, we estimated the risk of cancer in
relation to median organ doses for a range of
cardiac catheterisations carried out in the UK.
Radiation-induced cancers typically take many years
or even decades to develop,5 including those of
organs receiving the largest doses from cardiac
catheterisations —that is, the lungs, oesophagus,
stomach, and liver. Most risk projections assume
normal life expectancy, thus assume the patient will
live long enough for tumours to manifest. The sur-
vival of children with congenital heart disease
(CHD) is variable, however, ranging from around
20% to 90% at 12 years.6 For many conditions,
including isolated pulmonary valve stenosis and
atrial septal defect (ASD), survival approaches that
of the general population.7 For other patients,
including those with hypoplastic left heart syndrome
or those receiving transplanted organs, survival is
sufficiently reduced6 8 that the risk of radiation
induced cancer is substantially lower. In this study,
we have taken into account the impact of variable
survival on cancer risks by calculating risks as a
function of attained age, from 20 to 80 years.
METHODOLOGY
The lifetime attributable risk (LAR) of cancer inci-
dence (ie, in excess of background risk) was estimated
for 12 procedure types, based on the respective
typical radiation dose and age-at-exposure. The
median and interquartile range of ages at which each
procedure type is undertaken was calculated (table 1)
for 4574 cardiac catheterisations carried out since
2002 on patients aged under 22 years, at five UK hos-
pitals, using Siemens Axiom Artis or Artis Zee equip-
ment. Radiation doses were estimated for 2749
procedures falling within the respective interquartile
age range for each procedure type. Equivalent doses,
in millisieverts (mSv), were estimated for the lungs,
bone marrow, stomach, breasts, liver, and thyroid.
Doses to other organs, remote from the primary field
of irradiation, were sufficiently low for the risks to be
considered negligible.
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The methodology for dose estimation has been described pre-
viously.2 Briefly, examination-specific organ doses were esti-
mated from dose indicators recorded at the time of each
examination (kerma area product (PKA), also known as dose
area product), using a dosimetry system based on Monte Carlo
simulations (PCXMC V2.0), and incorporating data on projec-
tion angles and beam energy obtained from a sample of struc-
tured dose reports recorded for clinical examinations. A number
of modifications have since been made, including increasing the
field size for some procedure types, varying X-ray energy
according to patient size and accounting for table attenuation.
The overall impact of these changes has been a small reduction
in dose estimates.
Median organ doses for each of the 12 procedure types
carried out within the interquartile age range were calculated.
LAR was estimated in relation to median organ doses using the
following equation:
LAR(e, s, D) ¼
ðaMAX
eþL
ERR(e, s, D, a)m(s, a) S(s, a)
S(s, e)
 da
Here, the sex (s) specific elevated relative risk (ERR), as a func-
tion of age-at-exposure (e), organ dose (D) and attained age (a),
was based on models presented by the Biological Effects of
Ionizing Radiation (BEIR VII) committee.9 These are primarily
based on data from the cohort study of Japanese atomic
bombing survivors, though they also incorporate pooled ana-
lyses of data from other cohorts for breast and thyroid cancer.
Risks were calculated for each organ, using the respective
median equivalent dose and organ specific BEIR VII model.
The LAR is defined as the sum of risks between the
age-at-exposure plus a ‘latency period’ (L, which we set at
5 years for solid cancers and 2 years for leukaemia, based on
evidence from the atomic bombing survivors’ study5), and a
maximum age (aMAX), set at 100 years. The ERR model
assumes radiation induced cancer occurs in proportion to back-
ground rates, m(s, a). UK background rates for 2013 were
obtained from Cancer Research UK.10 The ‘survival function’ S
(s,a)/S(s,e) is the probability of being alive at an attained age of
a, conditional on reaching the exposure age e, thus starting at
1.0 and decreasing towards zero. Sex-specific figures for S(s, a),
representing normal life expectancy in the UK, for a birth year
of 2000, were obtained from the Office for National Statistics
(ONS). Given that individuals with CHD may have shorter life
expectancies, we performed a further analysis by calculating
LAR for attained ages of 20–80 years by varying aMAX and
setting the survival function to a constant value of 1.0.
LAR was also estimated using the alternative elevated absolute
risk (EAR) BEIR VII models, in which excess cancer risk is
assumed to be independent of background rates. Both ERR and
EAR models have advantages and disadvantages in terms of
closeness of fit to epidemiological data and transferability of risks
between populations. To account for this, a weighted sum of the
risks estimated using the ERR and EAR methodologies was calcu-
lated in linear space. We used the weightings recommended by
the BEIR VII committee: a 0.7/0.3 ERR/EAR weighting for leu-
kaemia and oesophageal, stomach, and liver cancers, while for
lung cancer, these weightings were reversed. For breast cancer, a
purely additive model was used, while risks for thyroid cancer
were based entirely on the ERR model. For all sites except leu-
kaemia, calculated risks were reduced by a ‘dose and dose rate
effectiveness factor’ (DDREF) of 1.5, designed to account for the
apparently lower risks at low doses (below 200 mSv).9
The study received a favourable ethical opinion from the
Newcastle and North Tyneside 2 Research Ethics Committee
(10/H0907/47), along with Confidentiality Advisory Group
approval for using patient identifiable data (ECC 7-04( j)/2010).
Local research and development approval was obtained from
participating hospitals supplying data.
RESULTS
The organ doses used in risk estimations are shown in the online
supplementary materials for this paper. The highest doses were
for the lungs (median for whole sample: 7.6 mSv), oesophagus
(5.1 mSv), and breasts (4.4 mSv). The LAR of cancer incidence
for individual sites, based on typical life expectancy in the UK
and median organ doses, are shown in table 2 for each examin-
ation type. For example, for every 100 000 males undergoing an
ASD occlusion at the representative age of 6.2 years, 9 would
develop lung cancer as a result (∼1 in 11 000). Equivalent figures
based on 25th and 75th percentiles for organ doses are included
in the online supplementary materials. Table 3 shows the attribut-
able risk of incidence of all cancers combined, including leukae-
mia, at attained ages (ie, the age the individual reaches) from 20
to 80 years. More detailed tables with a breakdown by individual
sites can be found in the online supplementary materials.
The LAR for all cancers is dominated by leukaemia below
attained ages of 30 years, with the contribution from cancers of
the lung, stomach, oesophagus, and liver rising steeply beyond
40–50 years.
Table 1 Median kerma area product and patient age and weight (interquartile range) for procedures used in risk estimations
Procedure type Sample size Kerma area product (Gy cm²) Patient age (years) Patient weight (kg)
ASD occlusion 435 1.7 (0.7–4.6) 6.2 (4.1–10.3) 21.3 (16.5–35.1)
PDA occlusion 890 1.3 (0.7–3.0) 1.8 (1.0–3.9) 10.8 (8.1–15.6)
Pulmonary valvuloplasty 316 1.3 (0.6–3.0) 0.5 (0.1–2.1) 7.1 (4.3–12.2)
Aortic valvuloplasty 165 2.0 (0.7–6.2) 0.9 (0.2–11) 9.2 (4.5–41.4)
PA balloon/stent 351 6.9 (2.9–14.7) 4.2 (1.6–9.8) 15.4 (9.9–27.3)
Coarctation balloon/stent 207 2.9 (1.4–10.6) 3.4 (0.4–12.7) 15.4 (6.2–44.5)
EPS/RFA 716 4.3 (1.5–12) 14.1 (11.7–15.9) 53.8 (41.4–64.0)
Heart biopsy 382 0.8 (0.4–1.9) 12.3 (4.2–15.1) 32.9 (15.5–49.2)
Coronary angiography 675 4.8 (2.4–10.8) 11.7 (6.9–14.9) 37.0 (22.0–52.0)
Valve replacement 38 32.2 (26.2–61.2) 14.8 (11.5–16.9) 45.0 (33.2–56.7)
Pacemaker procedures 246 1.2 (0.4–3.2) 13 (8.9–15.8) 40.8 (25.9–57.5)
Atrial septostomy 153 1.0 (0.3–2.5) 0.1 (0.0–2.9) 5.4 (3.5–15.1)
ASD, atrial septal defect; EPS, electrophysiology study; PA, pulmonary artery; PDA, patent ductus arteriosus; RFA, radiofrequency ablation.
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DISCUSSION
We have estimated the risk of developing cancer for a range of
procedure types, based on the typical age at exposure and
typical organ doses in UK practice for each procedure. We have
also taken potentially reduced survival into account by calculat-
ing risk up to attained ages ranging from 20 to 80 years. Table 4
shows a summary of these estimated risks in a form suitable for
communication of risks with patients, parents and stakeholders.
Where adjusted for age, dose, and value of DDREF, our esti-
mates of LAR appear to be reasonably similar to those of Beels
et al,11 who also applied BEIR VII risk models to organ doses
for 49 cardiac catheterisations done in Belgium, estimated from
Monte Carlo simulations. LAR for all cancers (incidence) was
reported as 0.076% and 0.205% for males and females, respect-
ively (76 and 205 per 100 000). The median effective dose was
6.4 mSv (organ doses were not stated).
The studies by Ait Ali et al12 and Johnson et al13 have the
advantage of including all radiation exposures, including CT,
allowing cumulative LAR to be calculated, though both appear
to have used effective dose and the ‘all solid cancers’ BEIR VII
model, rather than organ doses in their calculations. The former
study quotes median LAR estimates of 1 in 382 and 1 in 156
for males and females, respectively (262 and 641 per 100 000)
assuming exposure at 1 year.
As with our study, Johnson et al have accounted for reduced
survival in their risk estimates (Norwood and transplant
groups). Their methodology for achieving this was different
from ours, in that they replaced the BEIR VII models with the
ERR figure (0.035 mSv−1) reported in a recent study of cancer
incidence among children undergoing CT scans.14 Although it is
difficult to isolate the impact of this change, it appears to have
led to an increase, rather than a decrease, in estimated LAR,
which was quoted as 799 and 1677 per 100 000 for the
Norwood and transplant groups, respectively, based on respect-
ive cumulative effective doses of 28.9 and 63.8 mSv.
There is evidence that radiation induced cancers tend to
occur at ages at which they are normally observed in the general
population. For example, the number of excess cancers of the
lungs, stomach, and liver was close to zero among Japanese
atomic bombing survivors below attained ages of around
35 years.15 The risk of cancers of these organs is only likely to
be significant for patients expected to survive well into adult-
hood. There is some suggestion of relatively early onset of
breast cancer among children treated with radiotherapy,16 17
though early onset cases have been reported in patients treated
with chemotherapy/surgery alone.16 Early onset of leukaemia
and thyroid cancer has been observed in populations exposed to
radiation, though the doses from cardiac catheterisations to
bone marrow and the thyroid are relatively low.
Estimated risks were higher for females than for males, due to
both the higher risk per unit dose for many organs, and the
important contribution of breast cancer to the risk estimates.
There was no suggestion of systematic gender difference in
doses. Our dose reconstructions predict relatively high breast
doses in the lateral projection. However, this need not be the
case; with close collimation, ensuring the anterior chest wall is
Table 2 Estimated lifetime attributable risk per 100 000 of incidence of a range of cancers following different cardiac catheterizations
Cancer site
Procedure Lung Stomach Liver Oesophagus Breast Thyroid Leukaemia
Males
ASD occlusion 9 (4 to 20) 1 (1 to 2) 1 (1 to 2) 3 (0 to 6) n/a 0.1 (0 to 0.2) 1 (0 to 3)
PDA occlusion 20 (10 to 44) 2 (1 to 3) 2 (2 to 6) 7 (0 to 15) n/a 0.3 (0.1 to 1.1) 2 (0 to 5)
Pulmonary valvuloplasty 33 (16 to 72) 3 (2 to 6) 4 (3 to 8) 9 (0 to 21) n/a 0.5 (0.1 to 1.7) 4 (0 to 9)
Aortic valvuloplasty 28 (13 to 61) 2 (1 to 4) 3 (2 to 7) 9 (0 to 19) n/a 0.3 (0.1 to 1.2) 4 (0 to 9)
PA balloon/stent 54 (26 to 118) 4 (2 to 7) 7 (5 to 16) 14 (0 to 32) n/a 0.4 (0.1 to 1.6) 5 (0 to 12)
Coarctation balloon/stent 34 (16 to 74) 3 (1 to 5) 4 (3 to 9) 9 (0 to 21) n/a 0.3 (0.1 to 1.2) 4 (0 to 9)
EPS/RFA 16 (8 to 35) 1 (0 to 1) 1 (1 to 2) 4 (0 to 9) n/a 0 (0 to 0.1) 2 (0 to 5)
Heart biopsy 3 (2 to 7) 0 (0 to 0) 0 (0 to 1) 1 (0 to 2) n/a 0 (0 to 0) 1 (0 to 1)
Coronary angiography 17 (8 to 37) 1 (1 to 3) 1 (1 to 3) 5 (0 to 10) n/a 0.1 (0 to 0.2) 3 (0 to 6)
Valve replacement 113 (54 to 246) 6 (3 to 12) 10 (8 to 24) 26 (1 to 59) n/a 0.3 (0.1 to 1.2) 13 (1 to 29)
Pacemaker 7 (3 to 16) 1 (0 to 1) 1 (0 to 1) 2 (0 to 4) n/a 0 (0 to 0.1) 1 (0 to 3)
Atrial septostomy 16 (8 to 35) 1 (1 to 3) 2 (1 to 4) 5 (0 to 12) n/a 0.3 (0.1 to 0.9) 2 (0 to 5)
Females
ASD occlusion 26 (18 to 38) 1 (1 to 2) 0 (0 to 1) 2 (0 to 7) 17 (12 to 24) 0.2 (0.1 to 0.9) 1 (0 to 2)
PDA occlusion 54 (37 to 80) 2 (1 to 3) 2 (1 to 4) 4 (0 to 17) 75 (54 to 107) 1.4 (0.4 to 5.1) 2 (0 to 4)
Pulmonary valvuloplasty 58 (39 to 86) 3 (2 to 4) 2 (1 to 4) 5 (0 to 17) 68 (48 to 96) 1.5 (0.4 to 5.6) 2 (0 to 6)
Aortic valvuloplasty 90 (61 to 133) 3 (2 to 5) 2 (1 to 6) 6 (0 to 24) 104 (74 to 147) 1.5 (0.4 to 5.6) 4 (0 to 9)
PA balloon/stent 126 (85 to 185) 4 (3 to 6) 4 (1 to 10) 8 (0 to 32) 183 (132 to 259) 1.8 (0.5 to 6.5) 4 (0 to 9)
Coarctation balloon/stent 103 (69 to 151) 3 (2 to 5) 3 (1 to 7) 6 (0 to 23) 118 (85 to 167) 1.6 (0.4 to 5.9) 4 (0 to 10)
EPS/RFA 33 (22 to 48) 1 (1 to 1) 1 (0 to 1) 2 (0 to 8) 9 (7 to 13) 0.1 (0 to 0.5) 1 (0 to 3)
Heart biopsy 8 (6 to 12) 0 (0 to 0) 0 (0 to 0) 1 (0 to 3) 5 (4 to 8) 0 (0 to 0) 1 (0 to 1)
Coronary angiography 44 (30 to 65) 2 (1 to 3) 1 (0 to 2) 3 (0 to 12) 9 (6 to 12) 0.3 (0.1 to 1.1) 2 (0 to 6)
Valve replacement 311 (210 to 458) 11 (7 to 16) 7 (3 to 19) 20 (0 to 75) 335 (240 to 474) 2.3 (0.6 to 8.4) 14 (1 to 34)
Pacemaker 14 (9 to 20) 0 (0 to 1) 0 (0 to 1) 1 (0 to 3) 6 (4 to 8) 0.1 (0 to 0.5) 1 (0 to 1)
Atrial septostomy 51 (34 to 75) 2 (1 to 3) 1 (0 to 3) 4 (0 to 15) 50 (36 to 71) 1.2 (0.3 to 4.5) 3 (0 to 6)
Figures assume normal life expectancy, based on UK background rates. Figures in parentheses represent 95% confidence intervals based on risk model elevated relative risk and
elevated absolute risk coefficients.
ASD, atrial septal defect; EPS, electrophysiology study; PA, pulmonary artery; PDA, patent ductus arteriosus; RFA, radiofrequency ablation.
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entirely excluded from the primary radiation field, breast doses,
and associated risks, can be reduced by around 80%. Lung
dose may also be reduced through the use of lung ‘shuttering’
techniques. These practices should be especially encouraged for
pulmonary artery angioplasty and pulmonary valve replacement
—both relatively high dose procedures carried out on patients
with potentially good survival.
The risk estimates presented in tables 2 and 3 are based on
median organ doses for each procedure type. Considerable vari-
ation in dose is seen, however, from one procedure to the next,
or between different centres, depending on equipment and tech-
nique preferences.2 Risk estimates based on 25th percentiles of
organ doses (shown in the online supplementary materials) were
around 40% lower than those based on median doses, while
those based on 75th percentiles are around 80% higher. The
presented risk estimates are based on median ages at which each
procedure is done. The BEIR VII models used in our LAR
estimates assume risks fall with increasing age-at-exposure
(figure 1). Where procedures are commonly done at other ages,
we have provided further risk estimates, for all sites combined,
in the online supplementary materials, based on representative
median doses. A further table of LAR estimates is provided for
exposure ages of 0–20 years, based on median organ doses for
the whole cohort.
There are several sources of uncertainty in risk estimates
derived using the modelling approach. The uncertainty in the
Table 3 Estimated excess risk of cancer incidence, per 100 000, (lung, stomach, liver, thyroid, breast and leukaemia combined) as a function
of attained age
Procedure type
Attained age (years)
20 30 40 50 60 70 80
Males
ASD occlusion 1 (0 to 2) 1 (0 to 2) 1 (0 to 3) 2 (0 to 5) 4 (1 to 9) 9 (3 to 19) 16 (6 to 35)
PDA occlusion 2 (0 to 4) 2 (0 to 4) 3 (0 to 6) 4 (1 to 10) 9 (3 to 21) 19 (7 to 42) 35 (13 to 78)
Pulmonary valvuloplasty 3 (0 to 8) 4 (0 to 9) 5 (1 to 11) 8 (2 to 18) 16 (5 to 35) 31 (11 to 69) 57 (22 to 126)
Aortic valvuloplasty 3 (0 to 8) 4 (0 to 9) 5 (1 to 11) 7 (2 to 16) 14 (4 to 31) 27 (9 to 60) 49 (18 to 109)
PA balloon/stent 4 (0 to 8) 4 (1 to 10) 6 (1 to 14) 11 (3 to 24) 23 (7 to 51) 48 (17 to 106) 90 (35 to 198)
Coarctation repair 3 (0 to 7) 4 (0 to 8) 5 (1 to 10) 8 (2 to 17) 16 (5 to 35) 32 (11 to 70) 58 (22 to 128)
EPS/RFA 0 (0 to 1) 1 (0 to 2) 2 (0 to 3) 3 (1 to 6) 6 (2 to 14) 14 (5 to 30) 26 (9 to 56)
Heart biopsy 0 (0 to 0) 0 (0 to 1) 0 (0 to 1) 1 (0 to 2) 2 (0 to 3) 3 (1 to 7) 6 (2 to 12)
Coronary angiography 1 (0 to 2) 1 (0 to 3) 2 (0 to 5) 4 (1 to 8) 8 (2 to 17) 16 (5 to 35) 29 (11 to 64)
Valve replacement 2 (0 to 5) 5 (1 to 12) 9 (2 to 21) 19 (5 to 43) 45 (14 to 99) 96 (34 to 212) 182 (70 to 400)
Pacemaker 0 (0 to 1) 1 (0 to 1) 1 (0 to 2) 2 (0 to 3) 3 (1 to 7) 7 (2 to 15) 12 (4 to 27)
Atrial septostomy 2 (0 to 4) 2 (0 to 5) 3 (0 to 6) 4 (1 to 10) 8 (2 to 18) 16 (5 to 36) 29 (11 to 64)
Females
ASD occlusion 1 (0 to 1) 1 (0 to 2) 3 (1 to 5) 7 (4 to 11) 14 (9 to 22) 26 (17 to 41) 43 (28 to 68)
PDA occlusion 2 (0 to 4) 4 (2 to 7) 9 (5 to 16) 23 (15 to 36) 47 (31 to 73) 82 (54 to 128) 130 (86 to 202)
Pulmonary valvuloplasty 2 (0 to 5) 4 (2 to 8) 9 (5 to 16) 22 (14 to 36) 45 (29 to 72) 80 (52 to 125) 127 (83 to 200)
Aortic valvuloplasty 3 (1 to 8) 6 (2 to 12) 14 (8 to 24) 33 (21 to 53) 68 (45 to 107) 121 (80 to 189) 193 (127 to 301)
PA balloon/stent 3 (1 to 7) 8 (4 to 14) 21 (13 to 34) 53 (35 to 82) 110 (74 to 168) 193 (130 to 295) 305 (204 to 467)
Coarctation repair 3 (1 to 7) 6 (3 to 12) 15 (8 to 26) 37 (23 to 59) 77 (51 to 119) 137 (90 to 211) 218 (144 to 337)
EPS/RFA 0 (0 to 1) 1 (0 to 2) 2 (1 to 3) 5 (3 to 8) 12 (7 to 19) 24 (15 to 38) 42 (26 to 67)
Heart biopsy 0 (0 to 0) 0 (0 to 1) 1 (0 to 1) 2 (1 to 3) 4 (3 to 7) 8 (5 to 13) 14 (9 to 22)
Coronary angiography 1 (0 to 2) 1 (0 to 3) 3 (1 to 5) 6 (3 to 11) 15 (9 to 25) 31 (18 to 51) 54 (33 to 89)
Valve replacement 2 (0 to 5) 12 (6 to 22) 38 (23 to 61) 101 (66 to 157) 219 (145 to 336) 396 (262 to 610) 638 (421 to 987)
Pacemaker 0 (0 to 0) 0 (0 to 1) 1 (1 to 2) 3 (2 to 4) 6 (4 to 9) 11 (7 to 18) 19 (12 to 31)
Atrial septostomy 2 (0 to 5) 4 (1 to 8) 8 (4 to 14) 17 (10 to 29) 36 (23 to 57) 64 (41 to 101) 102 (66 to 162)
Figures in parentheses represent 95% confidence intervals for risk model elevated relative risk and elevated absolute risk coefficients.
ASD, atrial septal defect; EPS, electrophysiology study; PA, pulmonary artery; PDA, patent ductus arteriosus; RFA, radiofrequency ablation.
Table 4 Estimated lifetime risk of radiation induced cancer
incidence (all sites combined, risks rounded to the nearest hundred)
presented in the form 1 in x, for both normal and reduced life
expectancy
Procedure
Normal life
expectancy Survival to 50 years
Males Females Males Females
1 in: 1 in: 1 in: 1 in:
ASD occlusion 6600 2100 50 000 14 300
PDA occlusion 3000 700 25 000 4300
Pulmonary valvuloplasty 1900 700 12 500 4500
Aortic valvuloplasty 2200 500 14 300 3000
PA balloon/stent 1200 300 9100 1900
Coarctation balloon/stent 1800 400 12 500 2700
EPS/RFA 4200 2100 33 000 20 000
Heart biopsy 20 000 6700 100 000 50 000
Coronary angiography 3700 1600 25 000 16 700
Valve replacement 600 150 5300 1000
Pacemaker procedure 8300 4500 50 000 33 000
Atrial septostomy 3800 900 25 000 5900
Figures are based on typical organ doses in UK practice, based on kerma area
product levels given in table 1.
ASD, atrial septal defect; EPS, electrophysiology study; PA, pulmonary artery; PDA,
patent ductus arteriosus; RFA, radiofrequency ablation.
4 Harbron RW, et al. Heart 2016;0:1–6. doi:10.1136/heartjnl-2016-309773
Congenital heart disease
group.bmj.com on August 30, 2016 - Published by http://heart.bmj.com/Downloaded from 
value of ERR and EAR risk coefficients is reflected in 95% con-
fidence intervals incorporated into these estimates. A linear rela-
tionship between radiation dose and excess risk is assumed, with
no threshold dose below which there is no risk. This approach
is the basis for radiation protection standards in the UK. There
is currently insufficient evidence to confirm or refute alternative
proposals. The decision to use BEIR VII risk models, as
opposed to others developed by the International Commission
on Radiological Protection (ICRP)18 or the United Nations
Scientific Committee on the Effects of Atomic Radiation
(UNSCEAR)4 was arbitrary. Although all are based on the same
underlying data, the modifying effect of age-at-exposure varies
between models. In the ICRP approach, lung cancer ERR
increases with increasing age-at-exposure, in contrast to the
BEIR VII model. A sensitivity analysis was carried out by remov-
ing the age-adjustment term from the risk models for lung
cancer—meaning the risks do not vary with age-at-exposure.
This resulted in an average reduction in LAR, for all sites com-
bined, by 37% for males and 26% for females, assuming
normal life expectancy.
The decision to apply either multiplicative or additive meth-
odologies, or the weighting of both in the combined approach,
also lacks common consensus.19 ICRP 103 risk estimates utilise
equal ERR/EAR weightings for liver and stomach cancer and a
purely additive model for leukaemia.18 For the current study we
used the weightings recommended by the BEIR VII committee9
and the online risk calculation tool RadRat20 of 0.7/0.3 for all
three sites. Risk estimates based on relative risk transport are
also affected by regional variation in background rates. The esti-
mates presented in this study are based on UK-wide background
rates and may differ from those obtained using rates specific to
the region of residence of individual patients.
It should be noted that the estimated risks presented here are
specifically those related to radiation exposure and do not repre-
sent the overall risk of cancer in this group per se. Our risk esti-
mates are based on the assumption that background cancer rates
among people with CHD are the same as the general popula-
tion. A number of studies have suggested relatively high cancer
rates in this group, however,21 22 especially among those under-
going transplantation.23 Our risks based on ERR models may,
therefore, be underestimates, although the relative contribution
of radiation exposure and genetic factors to observed cancer
rates among CHD patients is currently unclear. Increasing back-
ground rates by 50% results in an increase in LAR for all sites
of 25% and 14% for males and females, respectively.
Conversely, the risk of lung cancer is influenced by smoking
rates, which tend to be relatively low24 among adults with
CHD. In this respect, our risk estimates for radiation induced
lung cancer may be overly pessimistic.
It is generally assumed that low doses (<200 mSv) or dose
rates (<0.1 mGy/min) result in a decreased risk, per unit dose,
compared to higher doses—hence the practice of reduction in
estimated LAR by a ‘DDREF’. The value of DDREF used in this
study (1.5) was equal to that used by the BEIR VII committee.9
Models presented in ICRP 10318 utilise a DDREF of 2.0, which
if adopted here, would lead to a reduction in LAR by 25%.
However, recent studies of cancer mortality in nuclear
workers25 26 and following CT scans14 27 do not suggest a
reduction in risk for low or protracted exposures, implying a
DDREF of no more than 1.0. Adopting a DDREF of 1.0 would
lead to an increase in estimated LAR by 33%.
Information on the latency period between exposure and
cancer development, which we set at 5 and 2 years for solid
cancers and leukaemia, respectively, is limited. The impact of
changes to the latency period for solid cancers is negligible as
the contribution to LAR from early years following exposure is
small. Leukaemia LAR estimates are more sensitive, however,
falling by around 25% when the latency period is doubled to
4 years.
Finally, risk estimation must also take into account the uncer-
tainty in dose estimates. The combined uncertainty due to vari-
ation in beam angle, X-ray energy, and field size from expected
values was estimated at around ±30%. This does not include
inherent uncertainty due to differences in organ shape and
density between the somewhat crude representation of the
human body (phantom) used in Monte Carlo simulations, and
real patients. The alternative methodology of using physical
measurements in tissue equivalent mannequins also involves a
number of anatomical approximations and it is not possible to
claim any one approach provides more accurate dose estimates
than the other. Breast dose errors are potentially large (up to
+200% and −90%) due to the difficulty in determining breast
inclusion within the primary field in the lateral projection. We
have assumed the thyroid is entirely excluded from the primary
beam, thus receiving a dose only from scattered radiation. If the
primary field includes the thyroid, the dose, and the associated
risk of cancer, increases by a factor ranging from 5 to 20
depending on patient size (frontal projection).
CONCLUSION
The risk of cancer associated with radiation exposures from
cardiac catheterisations is relatively low, considering the diag-
nostic and therapeutic value of these procedures. For the most
common procedures, assuming normal life expectancy, the
attributable risk of cancer was below 50 per 100 000 (0.05% or
1 in 2000) for males and 200 per 100 000 (0.2%, or 1 in 500)
for females. For those patients with reduced life expectancy,
Figure 1 Lifetime attributable risk
for all cancers combined as a function
of age-at-exposure. Upper and lower
bounds are based on 95% confidence
intervals of elevated relative risk (ERR)
and elevated absolute risk (EAR) risk
model coefficients. Risks based on
average dose for all procedures
combined.
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radiation related risks may be especially low. The risk of breast
cancer, especially following pulmonary artery angioplasty and
valve replacements, is the greatest concern.
Key messages
What is already known on this subject?
▸ The radiation exposure from cardiac catheterisations is
associated with an increased lifetime cancer risk. Most
previous assessments assume normal life expectancy and are
based on risks for all cancers combined.
What might this study add?
▸ The study provides information on site-specific risks based
on individual organ doses, and takes into account
potentially reduced survival among people with congenital
heart disease.
▸ Excluding valve replacements and biopsies, the average
lifetime risk is 1 in 3600 for males and 1 in 1400 for
females.
▸ For children with reduced survival chances, risks may be
reduced by a factor of 7 or more.
How might this impact on clinical practice?
▸ At current UK dose levels, the benefit from these procedures
far outweighs the risk of radiation induced cancer.
▸ Risks are strongly related to survival as most diseases will
not manifest until middle age.
▸ Care should be taken to avoid exposure of the breasts in the
lateral projection, where possible.
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